Posted by Michael Wonder on 11 Apr 2025
Biocon Biologics announces US FDA approval for Jobevne, biosimilar bevacizumab
10 April 2025 - Biocon Biologics today announced that the US FDA has approved Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use.
The approval for Jobevne (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, non-clinical, structural, analytical and functional data, which confirmed that Jobevne is highly similar to Avastin (bevacizumab).
